Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

S-TARget Achieves In Vivo Proof of Concept for Its Allergy Vaccine SG100

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
SG100 is being developed for the prevention and therapy of severe allergic asthma caused by house dust mite (HDM) allergens.

In a study of SG100 in naïve rhesus monkeys, S-TARget has demonstrated that repeated injections of the candidate vaccine induced a Th1 cell mediated memory immune response against natural HDM allergens. A Th1 immune response is considered a “healthy” immune response to allergens. By contrast, a Th2-mediated immune response can lead to allergic diseases—which in the case of exposure to HDM allergens include severe and persistent asthma. The study has also shown that SG100 can be safely applied in a relevant animal model.

“We are excited about the data from this study as it shows that S-TARget’s technology platform is safe and efficacious in a highly relevant animal model”, commented Geert Mudde, PhD, Chief Scientific Officer of S-TARget and Co-founder of the company.

Dr Mudde continued: “Based on this proof-of-concept study, we are currently initiating a follow-on study with SG100 in a clinically highly predictive non human primate animal model of house dust mite induced allergic asthma. The goal is to demonstrate the ability of SG100 to not only induce a Th1-mediated immune response, but to remodel existing ‘allergic’ Th2 cells into ‘healthy’ Th1 cells, thus triggering a normal immune response to future HDM exposure. SG100 is specifically designed for the human immune system (it will not work in rodents) to achieve exactly this remodeling of allergic Th2-cells. Such remodeling will provide a powerful therapeutic approach to directly address the causes of allergic diseases instead of just treating the symptoms”.

Follow-on study to reduce development risk; data expected in July

“The encouraging results achieved with SG100 are a major milestone for S-TARget”, commented Christof Langer, MBA, Chief Executive Officer and Co-founder of S-TARget. “We look forward to conducting the follow-on study of SG100 as it will be highly predictive of its subsequent development in the clinic. We believe that this approach will facilitate the clinical development. Moreover, it will significantly reduce the development risk of this program, making S-TARget an attractive target for future investors.” S-TARget expects the results of this study to be available in July 2013.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Fighting Cancer with the Power of Immunity
Researchers at MIT have used a combination of four different therapies to activate both of the immune system’s two branches, producing a coordinated attack that led to the complete disappearance of large, aggressive tumors in mice.
NIH Researchers Unveil New Wound-Healing Role for Protein-Folding Gene in Mice
The study found that topical treatment of an Hsp60-containing gel dramatically accelerates wound closure in a diabetic mouse model.
Ebola-Affected Countries Receive NIH Support
The National Institutes of Health has established a new program to further research capacity to study Ebola and other epidemics.
Skin Patch to Treat Peanut Allergy
NIH-funded study suggests peanut protein patch is a safe and convenient method of treatment.
Scientists Uncover Why Hepatitis C Vaccine is Difficult to Make
Scientists have uncovered one reason why a successful hepatitis C vaccine continues to be elusive.
Molecular Origins of Dust Mite Allergy Discovered
Scientists have identified molecules of house dust mites that are targeted by the immune system of children, developing allergic rhinitis and asthma.
Immunotherapy Technique Holds Promise for Curing Food Allergies
Scientists develop immunotherapy technique that almost eliminating allergic response and anaphylactic response in food-allergic mice.
Antibodies from Ebola Survivors Neutralize Virus, Protect Lab Mice
Scientists discover antiboides generated from the blood of Ebola survivors can strongly combat the virus in the lab.
Using CRISPR to Accelerate Search for HIV Cure
Gene-editing platform makes it easier to create HIV-resistant immune cells.
Sustained SIV Remission Achieved in Monkeys
Experimental treatment boosts monkey immune system to force SIV into sustained remission.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos